These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
28. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251 [TBL] [Abstract][Full Text] [Related]
29. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. Zhou JH; Cai JJ; She ZG; Li HL World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425 [TBL] [Abstract][Full Text] [Related]
30. NAFLD: Mechanisms, Treatments, and Biomarkers. Nassir F Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740949 [TBL] [Abstract][Full Text] [Related]
31. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
32. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310 [TBL] [Abstract][Full Text] [Related]
33. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Soejima Y; Fukusato T World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421 [TBL] [Abstract][Full Text] [Related]
39. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Tillman EJ; Rolph T Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084 [TBL] [Abstract][Full Text] [Related]
40. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]